Sernova Biotherapeutics (OTCMKTS:SEOVF) Posts Earnings Results, Hits Expectations

Sernova Biotherapeutics (OTCMKTS:SEOVF) posted its quarterly earnings results on Thursday. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.01), Zacks reports.

Sernova Biotherapeutics Price Performance

OTCMKTS:SEOVF remained flat at $0.11 during trading hours on Thursday. The company’s stock had a trading volume of 620 shares, compared to its average volume of 25,062. The stock has a fifty day simple moving average of $0.12 and a 200-day simple moving average of $0.11. Sernova Biotherapeutics has a one year low of $0.09 and a one year high of $0.16. The stock has a market cap of $41.54 million, a P/E ratio of -2.75 and a beta of 0.82.

Sernova Biotherapeutics Company Profile

Sernova Biotherapeutics is a clinical‐stage biotechnology company focused on developing and commercializing cell‐based therapeutic technologies for patients with chronic and life‐threatening diseases. Headquartered in London, Ontario, Canada, the firm is advancing an implantable device platform designed to support the long-term survival and function of therapeutic cells. The company’s lead product candidate, known as the Cell Pouch System, is engineered to create a vascularized environment in which transplanted cells can thrive, with an initial emphasis on treating patients with type 1 diabetes.

In its core program, Sernova has initiated a Phase I/II clinical trial evaluating the safety and efficacy of the Cell Pouch System in individuals with type 1 diabetes who require islet cell transplantation.